Cellectar Biosciences Inc  

(Public, OTCMKTS:CLRB)   Watch this stock  
Find more results for Simon Pedder�
0.350
+0.019 (5.74%)
Apr 17 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.33 - 0.35
52 week 0.25 - 0.47
Open 0.33
Vol / Avg. 5,714.00/32,057.00
Mkt cap 20.09M
P/E     -
Div/yield     -
EPS -0.19
Shares 57.40M
Beta 0.41
Inst. own 15%
Feb 11, 2014
NOVELOS THERAPEUTICS INC at Biotechnology Industry Organization CEO & Investor Conference
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -192.40% -117.88%
Return on average equity -517.07% -181.86%
Employees 24 -
CDP Score - -

Address

3301 Agriculture Drive
MADISON, WI 53716
United States - Map
+1-617-2441616 (Phone)
+1-608-4418121 (Fax)

Website links

Description

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc. is engaged in developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a phospholipid ether (PLE) platform technology as a targeted delivery and retention vehicle, its compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. The Company�s portfolio consists of PET imaging agents, optical imaging agents and therapeutic agents. The Company's I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. Its I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Its CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

Officers and directors

Stephen Anthony Hill M.D. Chairman of the Board
Age: 55
Simon Pedder Ph.D. President, Chief Executive Officer, Director
Age: 52
Joanne M. Protano C.P.A. Chief Financial and Accounting Officer, Vice President, Treasurer
Age: 44
Jamey P. Weichert Ph.D. Chief Scientific Officer, Director
Age: 57
Kathryn M. McNeil Vice President - Investor Relations, Public Relations and Corporate Communications
J. Patrick Genn Vice President - Business Development
Age: 56
Kevin Kozak M.D., Ph.D. Chief Medical Officer
Paul L. Berns Independent Director
Age: 47
John P. Neis Independent Director
Age: 57